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BACKGROUND
Diffuse low-grade and intermediate-grade gliomas (which together make up the 
lower-grade gliomas, World Health Organization grades II and III) have highly 
variable clinical behavior that is not adequately predicted on the basis of histo-
logic class. Some are indolent; others quickly progress to glioblastoma. The un-
certainty is compounded by interobserver variability in histologic diagnosis. Muta-
tions in IDH, TP53, and ATRX and codeletion of chromosome arms 1p and 19q 
(1p/19q codeletion) have been implicated as clinically relevant markers of lower-
grade gliomas.
METHODS
We performed genomewide analyses of 293 lower-grade gliomas from adults, in-
corporating exome sequence, DNA copy number, DNA methylation, messenger 
RNA expression, microRNA expression, and targeted protein expression. These 
data were integrated and tested for correlation with clinical outcomes.
RESULTS
Unsupervised clustering of mutations and data from RNA, DNA-copy-number, and 
DNA-methylation platforms uncovered concordant classification of three robust, 
nonoverlapping, prognostically significant subtypes of lower-grade glioma that 
were captured more accurately by IDH, 1p/19q, and TP53 status than by histologic 
class. Patients who had lower-grade gliomas with an IDH mutation and 1p/19q 
codeletion had the most favorable clinical outcomes. Their gliomas harbored mu-
tations in CIC, FUBP1, NOTCH1, and the TERT promoter. Nearly all lower-grade 
gliomas with IDH mutations and no 1p/19q codeletion had mutations in TP53 
(94%) and ATRX inactivation (86%). The large majority of lower-grade gliomas 
without an IDH mutation had genomic aberrations and clinical behavior strikingly 
similar to those found in primary glioblastoma.
CONCLUSIONS
The integration of genomewide data from multiple platforms delineated three 
molecular classes of lower-grade gliomas that were more concordant with IDH, 
1p/19q, and TP53 status than with histologic class. Lower-grade gliomas with an 
IDH mutation either had 1p/19q codeletion or carried a TP53 mutation. Most lower-
grade gliomas without an IDH mutation were molecularly and clinically similar to 
glioblastoma. (Funded by the National Institutes of Health.)
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Diffuse low-grade and intermedi-ate-grade gliomas (World Health Organi-zation [WHO] grades II and III, hereafter 
called lower-grade gliomas) (see the Glossary) 
are infiltrative neoplasms that arise most often 
in the cerebral hemispheres of adults and include 
astrocytomas, oligodendrogliomas, and oligoas-
trocytomas.1,2 Because of their highly invasive 
nature, complete neurosurgical resection is im-
possible, and the presence of residual tumor re-
sults in recurrence and malignant progression, 
albeit at highly variable intervals. A subset of 
these gliomas will progress to glioblastoma 
(WHO grade IV gliomas) within months, where-
as others remain stable for years. Similarly, sur-
vival ranges widely, from 1 to 15 years, and some 
lower-grade gliomas have impressive therapeutic 
sensitivity.3-5 Current treatment varies with the 
extent of resection, histologic class, grade, and 
the results of ancillary testing and includes clini-
cal monitoring, chemotherapy, and radiation 
therapy, with salvage options available in the 
event of treatment failure.6-8
Although the histopathological classification 
of lower-grade gliomas is time-honored, it suf-
fers from high intraobserver and interobserver 
variability and does not adequately predict clini-
cal outcomes.9,10 Consequently, clinicians increas-
ingly rely on genetic classification to guide clini-
cal decision making.11-14 Mutations in IDH1 and 
IDH2 (two very similar genes, hereafter referred 
to collectively as IDH) characterize the majority 
of lower-grade gliomas in adults and define a 
subtype that is associated with a favorable prog-
nosis.15-17 Lower-grade gliomas with both an IDH 
mutation (i.e., a mutation in either IDH1 or IDH2) 
and deletion of chromosome arms 1p and 19q 
(1p/19q codeletion), which occurs most often in 
oligodendrogliomas, have better responses to ra-
diochemotherapy and are associated with longer 
survival than diffuse gliomas without these al-
terations.5,18 TP53 and ATRX mutations are more 
frequent in astrocytomas and are also important 
markers of clinical behavior.19 To gain additional 
insight, we performed a comprehensive, integra-
tive analysis of 293 lower-grade gliomas from 
adults, using multiple advanced molecular plat-
forms. We performed an unsupervised analysis 
of integrated whole-genome molecular data to 
determine whether we could identify biologic 
classes of disease with clinically distinct behav-
ior and to determine whether these classes were 
captured more accurately by molecular-marker 
status than by histologic class.
Me thods
Patients
The tumor samples we analyzed were from 293 
adults with previously untreated lower-grade glio-
mas (WHO grades II and III), including 100 astro-
cytomas, 77 oligoastrocytomas, and 116 oligo-
dendrogliomas. Pediatric lower-grade gliomas 
were excluded; their molecular pathogenesis is 
distinct from that of lower-grade gliomas in 
adults.20,21 Diagnoses were established at the con-
tributing institutions; neuropathologists in our 
consortium reviewed the diagnoses and ensured 
the quality of the diagnoses and of the tissue for 
molecular profiling (see Supplementary Appen-
dix 1, available with the full text of this article 
at NEJM.org, for sample inclusion criteria). Pa-
tient characteristics are described in Table 1, and 
in Table S1 (Supplementary Appendix 2) and 
Table S2 in Supplementary Appendix 1. We ob-
tained appropriate consent from relevant institu-
tional review boards, which coordinated the con-
sent process at each tissue-source site; written 
informed consent was obtained from all partici-
pants. The patients’ ages, tumor locations, clini-
cal histories and outcomes, tumor histologic 
classifications, and tumor grades were typical of 
adults with a diagnosis of diffuse glioma.1,2
Analytic Platforms
We performed exome sequencing (289 samples), 
DNA copy-number profiling (285), messenger 
RNA (mRNA) sequencing (277), microRNA se-
quencing (293), DNA methylation profiling (289), 
TERT promoter sequencing (287), and reverse-
phase protein lysate array (RPPA) profiling (255).22 
Complete data for all platforms were available 
for 254 samples. Whole-genome sequencing and 
low-pass whole-genome sequencing were per-
formed on 21 and 52 samples, respectively. Mo-
lecular data were frozen on January 31, 2014, and 
clinical data were frozen on August 25, 2014. We 
also performed an unsupervised analysis (i.e., an 
analysis in which the categories are not known 
before computation) that integrated results from 
multiple platforms, including cluster of clusters 
(CoC) and OncoSign.23 In brief, CoC is a second-
level clustering of class assignments derived from 
each individual molecular platform. OncoSign 
A video summary 
is available at 
NEJM.org
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classifies tumors on the basis of similarities in 
recurrent mutations and copy-number variations.
The complete data sets are provided in Table 
S1 (Supplementary Appendix 2). The primary 
sequence files are deposited in CGHub (https:/ / 
 cghub . ucsc . edu); all other data, including muta-
tion annotation files, are deposited at the Cancer 
Genome Atlas Data Coordinating Center (http://
cancergenome . nih . gov). Sample lists, data ma-
trixes, and supporting data are available at the 
Cancer Genome Atlas lower-grade glioma publi-
cation page (https:/ / tcga-data . nci . nih . gov/ docs/ 
 publications/ lgg_2015).
Statistical Analysis
The statistical analysis included Fisher’s exact 
test for associations of categorical variables, 
one-way analysis of variance for association with 
continuous outcomes, Kaplan–Meier estimates 
of survival with log-rank tests among strata, and 
Cox proportional-hazards regression for multi-
ple-predictor models of survival. A complete 
description of the methods is provided in Sup-
plementary Appendix 1.
R esult s
Histologic and Molecular Subtypes
To compare the results from molecular plat-
forms with both histologic classification and 
classification based on markers frequently used 
in clinical practice (IDH mutation and 1p/19q 
codeletion), we classified lower-grade gliomas 
into three categories: gliomas with an IDH muta-
tion and 1p/19q codeletion, gliomas with an IDH 
mutation and no 1p/19q codeletion, and gliomas 
with wild-type IDH. We found a strong correla-
tion between the presence of an IDH mutation 
and 1p/19q codeletion and the oligodendroglio-
ma histologic class (69 of 84 samples) (Table 1, 
Adjusted Rand index: A measure of the similarity between two data clusterings, adjusted for chance grouping of the ele-
ments.
Cluster of clusters (CoC) analysis: A method of obtaining clusters (e.g., of patient samples) that represent a consensus 
among the individual data types (in this study, we incorporated DNA methylation, DNA copy number, mRNA ex-
pression, and microRNA expression into the analysis).
Double-minute chromosome–breakpoint-enriched region (DM-BER): As detected by whole-exome and whole-genome 
sequencing, highly amplified gene regions that are connected by DNA rearrangement breakpoints and allow cancer 
cells to maintain high levels of oncogene amplification.
Exon: The portion of a gene that encodes amino acids to form a protein.
Fusion transcript: A transcript composed of parts of two separate genes joined together by a chromosomal rearrange-
ment, in some cases with functional consequences for oncogenesis, therapy, or both.
Glioblastoma: The highest-grade (World Health Organization grade IV) and most frequently occurring form of diffusely 
infiltrative astrocytoma. It arises most often in the cerebral hemispheres of adults and is distinguished histopatho-
logically from diffuse lower-grade astrocytomas (grades II and III) by the presence of necrosis or microvascular pro-
liferation.
Lower-grade glioma: A diffusely infiltrative low-grade or intermediate-grade glioma (World Health Organization grade II 
or III) that arises most often in the cerebral hemispheres of adults and includes astrocytomas, oligodendrogliomas, 
and oligoastrocytomas.
Methylation: The attachment of methyl groups to DNA at cytosine bases. Methylation is correlated with reduced tran-
scription of the gene immediately downstream of the methylated site.
microRNA: A short regulatory form of RNA that binds to a target RNA and generally suppresses its translation by ribo-
somes.
Molecular subtype: Subgroup of a tumor type based on molecular characteristics (rather than, e.g., histologic or clinical 
features); in this study, a molecular subtype is one of three classes based on IDH mutation and 1p/19q codeletion 
status.
Mutation frequency: The number of mutations detected per megabase of DNA.
Significantly mutated gene: A gene with a greater number of mutations than expected on the basis of the background 
mutation rate, which suggests a role in oncogenesis.
Whole-exome sequencing: Sequencing of the coding regions, or exons, of an entire genome.
Whole-genome sequencing: Sequencing of the entire genome.
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Characteristic
Total 
(N = 278)†
IDH Mutation and 
1p/19q Codeletion 
(N = 84)
IDH Mutation and No 
1p/19q Codeletion 
(N = 139)
IDH Wild Type 
(N = 55)
Histologic type‡ and grade‡ — no. (%)
Oligodendroglioma
Grade II 65 (23) 38 (45) 21 (15) 6 (11)
Grade III 44 (16) 31 (37) 6 (4) 7 (13)
Oligoastrocytoma
Grade II 41 (15) 9 (11) 30 (22) 2 (4)
Grade III 33 (12) 4 (5) 20 (14) 9 (16)
Astrocytoma
Grade II 30 (11) 1 (1) 24 (17) 5 (9)
Grade III 65 (23) 1 (1) 38 (27) 26 (47)
Age at diagnosis — yr‡
Mean 42.6±13.5 45.4±13.2 38.1±10.9 49.9±15.3
Range 14–75 17–75 14–70 21–74
Male sex — no. (%) 155 (56) 45 (54) 84 (60) 26 (47)
White race — no./total no. (%)§ 261/274 (95) 79/81 (98) 131/138 (95) 51/55 (93)
Year of diagnosis — no. (%)
Before 2005 38 (14) 10 (12) 18 (13) 10 (18)
2005–2009 88 (32) 30 (36) 44 (32) 14 (25)
2010–2013 152 (55) 44 (52) 77 (55) 31 (56)
Family history of cancer — no./total no. (%)¶
None 108/190 (57) 30/58 (52) 64/98 (65) 13/34 (38)
Primary brain cancer 11/190 (6) 2/58 (3) 7/98 (7) 2/34 (6)
Other cancers 72/190 (38) 26/58 (45) 27/98 (28) 19/34 (56)
Extent of resection — no./total no. (%)
Open biopsy 6/268 (2) 1/81 (1) 4/132 (3) 1/55 (2)
Subtotal resection 98/268 (37) 31/81 (38) 45/132 (34) 22/55 (40)
Gross total resection 164/268 (61) 49/81 (60) 83/132 (63) 32/55 (58)
Tumor location — no. (%)‡
Frontal lobe 172 (62) 68 (81) 84 (60) 20 (36)
Parietal lobe 23 (8) 5 (6) 13 (9) 5 (9)
Temporal lobe 74 (27) 9 (11) 40 (29) 25 (45)
Other‖ 9 (3) 2 (2) 2 (1) 5 (9)
Laterality — no./total no. (%)
Left 133/276 (48) 37/84 (44) 69/137 (50) 27/55 (49)
Midline 5/276 (2) 2/84 (2) 2/137 (1) 1/55 (2)
Right 138/276 (50) 45/84 (54) 66/137 (48) 27/55 (49)
White matter — no./total no. (%) 74/144 (51) 26/48 (54) 37/72 (51) 11/24 (46)
First presenting symptom — no./total no. (%)
Headache 64/252 (25) 15/72 (21) 39/129 (30) 10/51 (20)
Mental status change 22/252 (9) 7/72 (10) 10/129 (8) 5/51 (10)
Motor or movement change 18/252 (7) 6/72 (8) 7/129 (5) 5/51 (10)
Table 1. Clinical Characteristics of the Sample Set According to IDH Mutation and 1p/19q Codeletion Status.*
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and Table S2 in Supplementary Appendix 1), a 
finding consistent with that in previous stud-
ies.24,25 Glioma samples with an IDH mutation 
and no 1p/19q codeletion (139 samples, 50% of 
the cohort) represented a mixture of histologic 
classes but were enriched for astrocytomas and 
oligoastrocytomas. IDH wild-type samples were 
mostly astrocytomas (31 of 55 samples) and 
grade III gliomas (42 of 55 samples), but this 
group included other histologic classes and 
grades. Overall, classification based on IDH–
1p/19q status correlated strongly with the oligo-
dendroglioma histologic class but only modestly 
with astrocytoma and oligoastrocytoma.
Multiplatform Integrative Analysis
To determine whether advanced molecular pro-
filing could subdivide lower-grade gliomas into 
discrete sets that are associated with biologic 
characteristics of disease, we performed unsuper-
vised clustering of molecular data derived from 
four independent platforms and found well-
defined clusters based on DNA methylation (five 
clusters) (Fig. S1 through S5 in Supplementary 
Appendix 1), gene expression (four clusters) 
(Fig. S6 and S7 in Supplementary Appendix 1 and 
Table S7 [Supplementary Appendix 6]), DNA copy 
number (three clusters) (Fig. S8 in Supplementary 
Appendix 1), and microRNA expression (four 
clusters) (Fig. S9 and S10 in Supplementary Ap-
pendix 1 and Table S8 [Supplementary Appendix 7] 
and Table S9 [Supplementary Appendix 8]).22,26,27
To integrate data and compare the resulting 
biologic classes with histologic classes and sub-
types based on IDH–1p/19q status, cluster group 
assignments from the four individual platforms 
(DNA methylation, mRNA, DNA copy number, 
and microRNA) were used for a second-level CoC 
analysis, resulting in three CoC clusters with dis-
tinctive biologic themes (Fig. 1). We found a strong 
correlation between CoC cluster assignment and 
molecular subtypes defined on the basis of IDH–
1p/19q codeletion status: most lower-grade glio-
mas with wild-type IDH were in the CoC cluster 
that included mRNA cluster R2, microRNA clus-
ter Mi3, DNA methylation cluster M4, and DNA 
copy number cluster C2. Another CoC cluster con-
tained almost all gliomas with an IDH mutation 
and 1p/19q codeletion and included primarily 
clusters R3, M2 and M3, and C3. The third CoC 
cluster was highly enriched for gliomas with an 
IDH mutation and no 1p/19q co deletion and in-
cluded clusters R1, M5, C1, and Mi1.
To determine the relative strength of clinical 
schemes for the classification of lower-grade 
gliomas in capturing the biologic subsets revealed 
by CoC analysis, we compared the correlation 
between IDH–1p/19q subtype and CoC cluster 
assignment with the correlation between histo-
logic class and CoC cluster assignment. Whereas 
90% of samples with a specific IDH–1p/19q desig-
nation mapped one-to-one with a predominant 
CoC cluster, only 63% of samples within a specific 
histologic class showed this predominant map-
ping. Moreover, the concordance between IDH–
1p/19q status and CoC cluster assignment was 
much greater than that between histologic sub-
type and CoC cluster assignment (adjusted Rand 
index, 0.79 vs. 0.19) (Table S2E in Supplementary 
Appendix 1), which indicates that IDH–1p/19q 
Characteristic
Total 
(N = 278)†
IDH Mutation and 
1p/19q Codeletion 
(N = 84)
IDH Mutation and No 
1p/19q Codeletion 
(N = 139)
IDH Wild Type 
(N = 55)
Seizure 135/252 (54) 38/72 (53) 70/129 (54) 27/51 (53)
Sensory or visual change 13/252 (5) 6/72 (8) 3/129 (2) 4/51 (8)
*  Plus–minus values are means ±SD. Categorical distributions were compared with the use of Fisher’s exact test. Analysis of variance was used 
to compare age between groups.
†  IDH–1p/19q status was not determined for 11 cases with clinical information.
‡  P<0.01 for the difference among the molecular subtypes.
§  Race was self-reported. Of the 261 patients who reported their ethnic background, 5% identified themselves as Hispanic or Latino.
¶  Included are patients for whom responses to questions regarding a family history of any cancer (192 patients) and a family history of primary 
brain cancer (197 patients) were available. P<0.05 for the difference among the molecular subtypes.
‖  One case (with wild-type IDH) was in the cerebellum, three cases were in the occipital lobe (two with IDH mutation and 1p/19q codeletion 
and one with an IDH mutation and no codeletion), and five cases were listed as “supratentorial, not otherwise specified” (one with an IDH 
mutation and no codeletion and four with wild-type IDH).
Table 1. (Continued.)
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status captures the biologic characteristics of 
lower-grade gliomas with greater fidelity than 
does histologic class.
Mutational Landscape of Lower-Grade 
Gliomas
We generated a consensus mutation set with the 
use of three mutation-calling algorithms (see the 
Methods section in Supplementary Appendix 1); 
this yielded 9885 mutations detected in 289 
samples (0.66 mutations per megabase in cod-
ing regions; median, 29 mutations per sample 
[range, 0 to 597]). Samples of lower-grade glio-
mas with wild-type IDH had more mutations 
(median, 45) than did samples with an IDH muta-
tion and 1p/19q codeletion (median, 27; P<0.001) 
or those with an IDH mutation and no 1p/19q 
codeletion (median, 28; P<0.001) (Fig. S11, S12, 
Figure 1. Cluster of Clusters (CoC) Analysis.
The results of multiplatform analyses point to biologic subtypes defined by IDH mutation and 1p/19q codeletion 
status. CoC analysis uses the cluster assignments derived from individual molecular platforms to stratify tumors, 
thereby integrating data from analysis of messenger RNA (mRNA) (designated by R on the y axis), microRNA (mi), 
DNA methylation (M), and copy number (C). For each sample, membership in a particular cluster is indicated by a 
yellow tick, and nonmembership is indicated by a blue tick. CoC analysis resulted in a strong three-class solution, 
and a comparison of tracks for CoC consensus cluster with tracks for histologic and molecular class shows a stron-
ger correlation with molecular class.
Grade
Histologic Class
Molecular Subtype
Consensus Cluster
mi2
R1
M5
C1
mi1
R3
M2
R2
R4
mi4
C2
mi3
M4
M3
M1
C3
mir_2
mRNA_1
methyl_5
cn_1
mir_4
mir_2
mRNA_1
methyl_5
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H
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D
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A
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A
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T
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T
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D
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C
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C
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A
H
T
A
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C
TC
G
A
H
T
A
5R
A
TC
G
A
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TC
G
A
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W
TC
G
A
C
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TC
G
A
C
S5395
TC
G
A
D
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G
A
D
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G
A
D
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G
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D
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C
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D
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G
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8011
TC
G
A
D
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G
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D
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G
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D
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G
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D
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D
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D
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G
A
D
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G
A
D
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TC
G
A
H
T
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G
A
H
T
7857
TC
G
A
H
T
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TC
G
A
H
T
A
4D
S
TC
G
A
D
HA66F
TC
G
A
Q
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TC
G
A
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D
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D
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T
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H
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A
D
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A
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D
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A
H
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G
A
D
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TC
G
A
D
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D
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G
A
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A
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A
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A
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A
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A
H
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A
C
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G
A
C
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G
A
C
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TC
G
A
H
T
7616
TC
G
A
D
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A
D
BA4X
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A
D
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A
D
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A
D
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H
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A
FG8186
TC
G
A
H
T
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A
H
T
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G
A
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G
A
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G
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D
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A
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A
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A
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D
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A
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A
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D
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A
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D
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A
H
T
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T
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T
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T
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A
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T
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T
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T
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T
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T
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D
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and S13 in Supplementary Appendix 1). The 
prevalence of mutations in lower-grade gliomas, 
per individual sample, was lower than that in 
glioblastoma, higher than that in medulloblas-
toma, and intermediate in the spectrum of Can-
cer Genome Atlas–reported cancers (Fig. S11 in 
Supplementary Appendix 1).22,28
We identified significant differences in DNA 
copy-number alterations and gene mutations 
among the three molecular subtypes (Fig. 2, 3, and 
4, and Fig. S8 and S14 in Supplementary Appen-
dix 1, Table S3 [Supplementary Appendix 3], and 
Table S4 in Supplementary Appendix 1). We found 
CIC mutations in 62% and FUBP1 mutations in 
29% of lower-grade gliomas with an IDH muta-
tion and 1p/19q codeletion, but we did not find 
these mutations in the other molecular subtypes. 
Among lower-grade gliomas with an IDH muta-
tion and 1p/19q codeletion, we also observed 
mutations in the PI3 kinase pathway genes PIK3CA 
(20%) and PIK3R1 (9%)29 and in NOTCH1 (31%),29-31 
as well as novel mutations in ZBTB20 (9%) and 
ARID1A (6%) (Fig. 2). In addition, among lower-
grade gliomas with an IDH mutation and 1p/19q 
codeletion, 96% carried activating TERT promoter 
mutations, leading to elevated TERT expression; 
ATRX mutations were rare in these tumors, a 
finding consistent with the mutual exclusivity of 
ATRX and TERT mutations14,32 (Fig. 2 and 3). Fo-
cal amplification of 19p13.3 was noted (Fig. 3, 
and Fig. S14A in Supplementary Appendix 1), but 
few recurring whole-arm copy-number alterations 
other than 1p/19q codeletion were observed (Fig. 
S8B in Supplementary Appendix 1). Differences 
in the prevalence of mutations and the pattern 
of copy-number alterations between grade II and 
grade III lower-grade gliomas with an IDH muta-
tion and 1p/19q codeletion were modest (Fig. 5A, 
and Fig. S21 in Supplementary Appendix 1).
Overall, the data suggest that lower-grade 
gliomas with an IDH mutation and 1p/19q co-
deletion are biologically discrete and arise from 
a sequence of IDH mutation, 1p/19q codeletion, 
and TERT activation; mutation of CIC and FUBP1; 
and activating alterations in the PI3 kinase path-
way.29,31,32 NOTCH1 mutations in this subset of 
tumors probably inactivate the gene, because they 
occur at positions similar to those of NOTCH1 
inactivating mutations in lung, head and neck, 
and cervical cancers and not at activation sites34 
(Fig. S15 in Supplementary Appendix 1). The re-
sults of a PARADIGM-SHIFT35 analysis (Fig. S16 
in Appendix 1), in which downstream targets 
are evaluated to assess pathway status, also sug-
gested that NOTCH1 mutations result in inactiva-
tion of NOTCH1 protein function. Previous 
studies identified NOTCH1 mutations in oligoden-
droglioma and anaplastic astrocytoma; we noted 
them most often in lower-grade gliomas with an 
IDH mutation and 1p/19q codeletion, and they 
were rarely identified in lower-grade gliomas with 
an IDH mutation and no 1p/19q codeletion or in 
those with wild-type IDH (Fig. 2).29-31
Nearly all lower-grade gliomas with an IDH 
mutation and no 1p/19q codeletion (94%) har-
bored TP53 mutations, which suggests that this 
tumor class is defined by a loss of p53 function. 
Inactivating alterations of ATRX were frequent 
(86%) and included mutations (79%), deletions 
(3%), gene fusion (2%), or a combination of these 
events (2%).19 TERT promoter mutations were 
rare (4%), a finding consistent with the alterna-
tive mechanism of lengthening telomeres that is 
associated with ATRX mutations.32 We observed 
two novel significantly mutated genes in lower-
grade gliomas with an IDH mutation and no 
1p/19q codeletion: the SWI/SNF chromatin re-
modeler SMARCA4 (in 6% of these gliomas), 
which was previously implicated in glioma pro-
gression,36 and the translation initiation factor 
EIF1AX (in <1%), which was previously document-
ed in uveal melanoma37 (Fig. 2, and Table S4 in 
Supplementary Appendix 1). Some lower-grade 
gliomas with an IDH mutation and no 1p/19q 
codeletion had focal gains of 4q12, a locus har-
boring PDGFRA, which encodes a receptor tyrosine 
kinase; 12q14, encompassing CDK4, which en-
codes a cell-cycle regulator; or 8q24, a broad am-
plicon that includes MYC (Fig. S14A in Supplemen-
tary Appendix 1). These findings are consonant 
with those in previous studies of proneural 
glioblastoma with mutated IDH1 (with respect to 
MYC amplification) and with wild-type IDH1 (with 
regard to CDK4 and PDGFRA amplification).22 
Histologic grade III tumors in this subset had 
greater frequencies of chromosome 9p and 19q 
losses and of 10p gains (Fig. 5A), yet the muta-
tional profiles did not differ substantially between 
grades (Fig. S21B in Supplementary Appendix 1). 
In the class of lower-grade gliomas with an IDH 
mutation, our multiplatform analysis suggests 
that there is a molecular progression that starts 
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Figure 3. OncoSign Analysis.
Four main classes (OncoSign classes [OSCs]) can be identified by means of unbiased clustering of tumors on the basis of recurrent copy-
number alterations, mutations, and gene fusions. White indicates that no information was available. OSCs are largely consistent with the 
molecular subtypes identified on the basis of IDH mutation and 1p/19q codeletion status, and they also correlate with the results of single-
platform analysis. Combinations of selected genomic events, termed oncogenic signatures, characterize each OSC. A small group of sam-
ples showed none of the recurrent events used in this analysis and were therefore categorized as unclassified. TERT promoter mutation 
and gene overexpression were found to be mutually exclusive with loss of ATRX and reduced gene expression, a finding consistent with 
the hypothesis that both alterations have a similar effect on telomere maintenance. The abbreviation miRNA denotes microRNA, and 
RPPA reverse-phase protein lysate array.
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with initial IDH mutation and acquisition of 
the glioma CpG island methylation phenotype 
(G-CIMP, a specific pattern of widespread DNA 
hypermethylation) and is followed by either 
1p/19q codeletion or TP53 mutation.19,31,38
 Signaling Networks in Lower-Grade Glioma
To incorporate mutational landscapes into an 
unsupervised multiplatform classification, we 
performed OncoSign analysis23 with the use of 
70 selected genetic events (mutation and copy 
number alteration) and identified four dominant 
subtypes (OSC1 to OSC4), which again largely 
recapitulated those defined by IDH–1p/19q status 
(adjusted Rand index, 0.83) (Fig. 3, and Table 
S2E in Supplementary Appendix 1). OSC1 was 
strongly correlated with lower-grade gliomas 
with an IDH mutation and no 1p/19q codeletion, 
and OSC4 contained exclusively lower-grade glio-
mas with wild-type IDH. The group with an IDH
mutation and 1p/19q codeletion included both 
OSC2 and OSC3 lower-grade gliomas, which dif-
fered from one another with regard to mutations 
in CIC, FUBP1, and NOTCH1 yet were not substan-
tially different in terms of tumor grade or pa-
Figure 4. Summary of Major Findings.
Shown is a schematic representation that summarizes the major molecular findings and conclusions of our study: consensus clustering 
yielded three robust groups that were strongly correlated with IDH mutation and 1p/19q codeletion status and had stereotypical and 
subtype-specific molecular alterations and distinct clinical presentations. GBM denotes glioblastoma, and LGG lower-grade glioma.
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Figure 5 (facing page). LGGs and GBMs with Wild-Type 
IDH.
Panel A shows the frequency of large-scale copy-num-
ber alterations in specific molecular subtypes of LGG, 
which have been divided according to histologic grade. 
The University of California, Santa Cruz (UCSC), Can-
cer Genomics Browser33 (https:/ / genome-cancer . ucsc . -
edu) was used to visualize GISTIC thresholded copy-
number calls across the indicated chromosomes. Each 
vertical line indicates the copy number for an individu-
al sample, colored red (amplification), blue (deletion), 
or white (normal), at each genomic position. Percent-
ages for the indicated copy-number alteration are 
shown in the bar graphs on the right. LGGs with wild-
type IDH had frequencies of gains and losses similar 
to those of GBMs with wild-type IDH (from previously 
published Cancer Genome Atlas data22) and were dis-
tinct from LGGs with mutated IDH. DM/HSR denotes 
double-minute chromosomes or homogeneously stain-
ing regions. Panel B shows the frequencies in the indi-
cated LGG molecular subtypes of mutational events 
that are commonly found in GBM with wild-type IDH, 
including LGGs with IDH mutation and 1p/19q codele-
tion (85 samples), IDH mutation and no codeletion 
(141), and wild-type IDH (56). SNV denotes single-nu-
cleotide variant, and SV structural variant. Differences 
in mutational frequency according to tumor grade are 
shown in Fig. S21 in Supplementary Appendix 1.
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tient outcome. The concordance between IDH–
1p/19q status and classes based on two different 
multiplatform approaches to genomic data inte-
gration (CoC and OncoSign) is striking and con-
trasts sharply with the much weaker correlation 
between histologic subtypes and unsupervised 
multiplatform classes (Table S2E in Supplemen-
tary Appendix 1). The finding that widely avail-
able markers (IDH and 1p/19q) can be used to 
classify lower-grade gliomas with results similar 
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to those obtained through the unsupervised strat-
ification of genomewide molecular data provides 
an unbiased, data-driven rationale for using IDH 
and 1p/19q markers to identify lower-grade glio-
ma disease classes and to incorporate them into 
a contemporary clinical classifier.11,14,39,40
Lower-Grade Gliomas and Glioblastoma  
with Wild-Type IDH
Mutations in seven genes were strongly associat-
ed with lower-grade gliomas that had wild-type 
IDH. Five of these genes have been reported to be 
mutated in glioblastoma: PTEN (in 23% of lower-
grade gliomas with wild-type IDH), EGFR (in 27%), 
NF1 (in 20%), TP53 (in 14%), and PIK3CA (in 
9%).22 We also found novel mutations in PTPN11, 
which encodes protein tyrosine phosphatase non-
receptor 11 (in 7%), and in PLCG1, which en-
codes phospholipase C gamma 1 (in 5%) (Fig. 2). 
Similarly, copy-number alterations in tumors 
with wild-type IDH were distinct from lower-
grade gliomas with mutated IDH and instead 
resembled glioblastomas with wild-type IDH 
(Fig. 5A). In particular, gains of chromosome 7 
and deletions of chromosome 10 co-occurred in 
more than 50% of tumors of this subtype (chro-
mosome 7 gains, 56%; chromosome 10 dele-
tions, 63%), yet these alterations were absent in 
groups with mutated IDH. Recurring focal ampli-
fications containing EGFR, MDM4, and CDK4 (in 
38%, 13%, and 7% of tumors, respectively) and 
focal deletions targeting CDKN2A and RB1 (in 63% 
and 25%, respectively) were the most common 
acquired copy-number variants in lower-grade 
gliomas with wild-type IDH, findings similar to 
those for glioblastomas with wild-type IDH 
(Fig. 5B). Grade II gliomas with wild-type IDH 
were uncommon (13 cases), yet they differed from 
those that were grade III (Fig. S21C and S21D in 
Supplementary Appendix 1) in that they were 
strongly enriched within the discrete M1 DNA 
methylation cluster (Fig. 1, and Fig. S1A in Sup-
plementary Appendix 1). Lower-grade gliomas in 
the M1 cluster that had wild-type IDH and were 
of grade II had a low prevalence of mutations 
and copy-number alterations, and they did not 
have TERT promoter mutations, which poten-
tially indicates that they are distinct pathologic 
entities. TERT promoter mutations were present 
in 64% of all lower-grade gliomas with wild-type 
IDH; when M1 lower-grade gliomas were excluded 
from the analysis, TERT promoter mutations 
were present in 80% of those remaining, a preva-
lence similar to that in primary glioblastoma.32
Genomic Rearrangements and Fusion 
Transcripts
We investigated 20 samples with the use of high-
coverage whole-genome sequencing, 50 samples 
with low-coverage whole-genome sequencing, 
and 311 samples with whole-exome sequencing, 
for structural chromosomal variants (e.g., trans-
locations and inversions); we uncovered, with 
high confidence, 250 chromosomal rearrange-
ments (Table S5 [Supplementary Appendix 4]). 
In addition, 19 samples had evidence of extra-
chromosomal DNA structures known as double-
minute chromosomes–breakpoint-enriched regions 
(DM-BERs) (Table S5 [Supplementary Appendix 
4] and Fig. S17 in Supplementary Appendix 1). 
Of these, 15 occurred in lower-grade gliomas 
with wild-type IDH (27% of the samples) 
(Fig. 5A), a frequency similar to that seen with 
glioblastoma (23%).41,42 In an analysis of RNA 
sequencing data, we identified fusion transcripts 
in 265 lower-grade gliomas (Table S6 [Supplemen-
tary Appendix 5]), and correlation with structural 
genomic variants suggested chimeric transcrip-
tion for 44% of the high-confidence chromo-
somal rearrangements, including two EGFR fu-
sions (Fig. 5B), and for 58% of DM-BERs.43,44 
Several genes (EGFR, FGFR3, NOTCH1, ATRX, and 
CDK4) were affected by fusions in multiple sam-
ples (Fig. S18A and S18B in Supplementary Ap-
pendix 1). Fusions that were predicted to activate 
EGFR and FGFR3 were restricted to lower-grade 
gliomas with wild-type IDH and were noted at 
frequencies similar to those in glioblastoma (7% 
and 3%, respectively) (Fig. S18A, S18B, and S19 
in Supplementary Appendix 1).45,46 A novel chi-
meric FGFR3-ELAVL3 transcript involved the same 
breakpoint as previously reported for FGFR3-TACC3 
fusions and was highly expressed, which sug-
gests that it could have similar effects on FGFR3 
function. Three samples had fusions between 
EGFR and intergenic or intronic chromosome 7 
regions that are predicted to remove the EGFR 
autophosphorylation domain and are likely to be 
oncogenic (Fig. S18 in Supplementary Appendix 
1).47 Fusions involving genes encoding receptor 
tyrosine kinases were predominantly a feature of 
lower-grade gliomas with wild-type IDH; only 
two lower-grade gliomas with an IDH mutation 
and no 1p/19q codeletion harbored such fusions 
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(involving PDGFRA and MET), and none were 
identified among lower-grade gliomas with an 
IDH mutation and 1p/19q codeletion.
Protein Expression
RPPA analysis resulted in protein-expression pro-
files that showed a striking segregation of lower-
grade gliomas with wild-type IDH from those 
with mutated IDH, as well as the activation of 
receptor tyrosine kinase pathways (such as the 
EGFR pathway) in tumors with wild-type IDH, 
which provides additional support for the bio-
logic similarity between lower-grade gliomas 
with wild-type IDH and glioblastoma (Fig. S20 in 
Supplementary Appendix 1). We observed over-
expression of HER2, a potential therapeutic tar-
get, in tumors with wild-type IDH. Among lower-
grade gliomas with mutated IDH, we observed 
higher expression of tyrosine protein kinase SYK, 
E-cadherin, and annexin 1 in the group without 
1p/19q codeletion. Among lower-grade gliomas 
with an IDH mutation and 1p/19q codeletion, we 
noted higher levels of HER3 with a phosphory-
lated tyrosine residue at position 1289, a marker 
that potentially confers resistance to PI3 kinase 
inhibitors.48
From Signatures to Pathways
To gain insights into signaling pathways, we per-
formed an integrated analysis of mutations, focal 
copy-number alterations, structural variants, and 
fusions affecting genes that encode receptor tyro-
sine kinases (EGFR, PDGFRA, MET, and FGFR), 
PI3 kinase subunits, MAP kinases NF1 and BRAF, 
components of the p53 and RB1 pathways 
(MDM2, MDM4, MDM1, CDKN2A and CDKN2B 
[hereafter referred to as CDKN2A/B], and CDKN2C), 
and ATRX. Alterations across these loci were re-
markably similar in frequency between lower-
grade gliomas with wild-type IDH and glioblas-
tomas with wild-type IDH but not between these 
groups and other subtypes of lower-grade glioma 
(Fig. 5B, and Fig. S21E in Supplementary Appen-
dix 1).22 A total of 43% of lower-grade gliomas 
with wild-type IDH and 53% of glioblastomas 
with wild-type IDH harbored EGFR alterations, 
with EGFR amplification being the most com-
mon aberration in both (Fig. S21 in Supplemen-
tary Appendix 1). Homozygous CDKN2A/B dele-
tions occurred in 45% of lower-grade gliomas 
with wild-type IDH, which is similar to the fre-
quency of these deletions in glioblastomas with 
wild-type IDH (55%). This contrasts with lower-
grade gliomas with an IDH mutation and no 
1p/19q codeletion, in which large single-copy 
deletions of chromosome 9p were common, yet 
CDKN2A/B was homozygously deleted in only 4% 
(Fig. S14B in Supplementary Appendix 1). Lower-
grade gliomas with mutated IDH did not have 
cancer pathway aberrations similar to those of 
glioblastoma with wild-type IDH; instead, they 
had characteristic cancer pathway alterations in 
TP53 and ATRX (in the group with IDH mutation 
and no 1p/19q codeletion) and in TERT, NOTCH1, 
CIC, and FUBP1 (in the group with IDH mutation 
and 1p/19q codeletion) (Fig. S21E in Supplemen-
tary Appendix 1).
Clinical Characteristics and Outcomes 
Associated with Molecular Subtypes
Patients who had lower-grade gliomas with wild-
type IDH were older than those who had lower-
grade gliomas with mutated IDH and were more 
likely to have a family history of cancer (Table 1, 
and Table S2 in Supplementary Appendix 1). The 
anatomical locations of the tumors also differed; 
lower-grade gliomas with mutated IDH arose in 
frontal lobes more often than did those with 
wild-type IDH (P<0.05). Among the patients for 
whom clinical follow-up data were available, 77 of 
250 (31%) had tumor recurrence, and 60 of 289 
(21%) were deceased at the time of analysis. Pa-
tients who had lower-grade gliomas with wild-
type IDH had substantially shorter overall sur-
vival than did those with lower-grade gliomas 
with mutated IDH (age-adjusted hazard ratio for 
death, 7.4; 95% confidence interval, 4.0 to 13.8). 
Their prognosis (median survival, 1.7 years) was 
intermediate between those of persons who had 
glioblastomas with wild-type IDH (median sur-
vival, 1.1 years) and persons who had glioblasto-
mas with mutated IDH (median survival, 2.1 years) 
(Fig. 6B, and Table S2D in Supplementary Appen-
dix 1). In comparison, persons who had lower-
grade gliomas with an IDH mutation and 1p/19q 
codeletion had a median survival of 8.0 years, 
and those with an IDH mutation and no codele-
tion had a median survival of 6.3 years.
The molecular classification of lower-grade 
gliomas as having wild-type IDH, IDH mutation 
with no 1p/19q codeletion, or IDH mutation with 
1p/19q codeletion stratified patient outcomes in 
multiple-predictor models after adjustment for 
age and extent of resection (Table S2B, S2C, and 
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S2D in Supplementary Appendix 1). Grade, but 
not histologic class, remained a significant pre-
dictor of outcome in multivariable models with 
IDH–1p/19q status and provided additional prog-
nostic value among the molecular subsets (Table 
S2 and Fig. S22 in Supplementary Appendix 1). 
Together, the results point to three robust tumor 
classes in lower-grade glioma, each with proto-
typical molecular alterations and distinctive 
clinical behavior (Fig. 4 and 6B).
Discussion
We used a comprehensive, multiplatform genom-
ics approach to delineate the biologic founda-
tions of adult lower-grade glioma and conclude 
that genetic status was more reflective of disease 
subtypes than was histologic class. We base this 
conclusion on the results of an unsupervised 
analysis of genomewide molecular platforms, in 
which we identified three cohesive tumor classes 
that had distinct clinical behavior and were con-
cordant with IDH, 1p/19q, and TP53 status to a 
greater extent than with histologic class. The 
three nonoverlapping molecular subtypes dis-
tilled from the six histologic and grade combi-
nations lay the foundation for a reproducible and 
clinically relevant classification that incorpo-
rates molecular data into the pathological diag-
nosis, as is planned for the upcoming revision 
of the WHO classification of brain tumors.39,40 
More specifically, we observed that two unsuper-
vised, integrative genomewide analyses indepen-
dently uncovered three primary lower-grade glio-
ma disease classes that were best represented by 
IDH and 1p/19q status; that lower-grade gliomas 
with an IDH mutation had either 1p/19q codele-
tion or a TP53 mutation in a mutually exclusive 
fashion, which indicates a strict molecular di-
chotomy; and that the majority of lower-grade 
gliomas with wild-type IDH showed remarkable 
genomic and clinical similarity to primary (wild-
type IDH) glioblastoma.
Numerous studies have shown that the histo-
pathological classification of diffuse gliomas is 
prone to high interobserver variation, correlates 
inconsistently with genetic markers, and imper-
fectly predicts clinical outcomes.9,10 Like others, 
we found that lower-grade gliomas with an IDH 
mutation and 1p/19q codeletion were of the oligo-
dendroglioma histologic class and were associ-
ated with favorable outcomes.1,4,14,18,24,49 However, 
lower-grade gliomas with wild-type IDH and 
those with mutated IDH and no 1p/19q codele-
tion had substantial representation from all three 
histologic classes (astrocytoma, oligodendrogli-
Figure 6. Clinical Outcomes.
Panel A shows Kaplan–Meier estimates of overall survival among patients 
with LGGs that are classified according to traditional histologic type and grade. 
GBM samples (from previously published Cancer Genome Atlas data22) are 
also included for comparison. Panel B shows overall survival among patients 
with LGGs that are classified according to IDH mutation and 1p/19q codele-
tion status. GBM samples classified according to IDH mutation status are 
also included. The results of an age-adjusted analysis are provided in Table 
S2 in Supplementary Appendix 1, and further division according to histologic 
type, grade, and molecular subtype is shown in Fig. S22 in Supplementary 
Appendix 1.
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oma, and oligoastrocytoma), which highlights 
the discordance between histologic and genetic 
markers. In comparison, two unsupervised meth-
ods that integrated multiplatform molecular data 
(CoC and OncoSign) yielded strong correlations 
with IDH–1p/19q status (adjusted Rand index, 
0.79 and 0.83, respectively), which showed that 
molecular classification captured biologic class-
es of disease more accurately than did histologic 
classification.
In addition, whereas oligodendrogliomas typ-
ically had 1p/19q codeletion and astrocytomas 
typically did not, oligoastrocytomas were dis-
tributed among the three molecular subtypes 
with no molecular feature distinguishing them. 
Thus, although previous WHO classifications have 
recognized lower-grade gliomas with mixed his-
tologic features (oligoastrocytoma), our results 
indicate that lower-grade gliomas with an IDH 
mutation have either 1p/19q codeletion or a TP53 
mutation, with few gaps or overlaps, reflecting 
two distinct molecular mechanisms of oncogene-
sis, and they do not provide evidence for a bio-
logic or genetic signature specific to oligoastro-
cytoma (Fig. 2, 3, and 4); this observation is 
consistent with those in previous studies.38,49-51 
Molecular signatures of lower-grade glioma lend 
themselves to a practice-altering, biologically 
based classification system that should improve 
interobserver concordance. The implementation 
of this type of system also seems likely to reduce 
the diagnosis of “oligoastrocytoma” and the con-
fusion related to its clinical management.
Another substantial finding was that tumors 
with wild-type IDH were molecularly and clini-
cally distinct from subtypes with mutated IDH, 
with most showing a striking resemblance to 
primary glioblastoma on all analytic platforms. 
These findings suggest that lower-grade gliomas 
with wild-type IDH are likely to be immediate 
precursors of glioblastoma with wild-type IDH, 
since the median survival associated with this 
type of lower-grade glioma was only slightly 
longer than that associated with this type of 
glioblastoma (Fig. 6B). Alternatively, such tumors 
could represent glioblastomas that were incom-
pletely sampled during surgery, in which case 
definitive histologic classification would be pre-
cluded. From a practical standpoint, sampling 
errors represent a challenge in surgical neuropa-
thology, regardless of IDH status, class, or grade, 
because a histologic diagnosis is limited to find-
ings under the microscope. Thus, molecular clas-
sification based on IDH–1p/19q status represents 
an improvement in diagnostic practice because it 
enables the identification of a clinically aggres-
sive form of lower-grade glioma (with wild-type 
IDH) in the absence of morphologic criteria for 
glioblastoma.15,17
Our analysis of clinical outcomes showed 
that persons who had lower-grade gliomas with 
an IDH mutation and no 1p/19q codeletion had 
shorter overall survival than did those who had 
lower-grade gliomas with an IDH mutation with 
codeletion, yet both of these groups had sub-
stantially longer overall survival than did persons 
who had lower-grade gliomas with wild-type 
IDH.15 The stratification of clinical risk on the 
basis of IDH–1p/19q status is more robust than 
outcome predictions based on histologic class 
(Fig. 6, and Table S2 and Fig. S22 in Supplemen-
tary Appendix 1). Molecular classification can 
also provide quality control for histopathological 
diagnosis. For example, tumors in the small, 
discrete DNA methylation cluster M1 had a low 
frequency of mutations and copy-number altera-
tions, yet tumors in this group occasionally con-
tained BRAF alterations. Although they are not 
entirely specific, these alterations are more char-
acteristic of grade I circumscribed tumors, such 
as pilocytic astrocytoma and ganglioglioma, and 
their presence would prompt consideration of 
alternative diagnoses.1,13 Although diffuse glio-
mas and circumscribed gliomas can occasion-
ally overlap histologically, their associated prog-
nosis and clinical management differ greatly. 
Molecular signatures offer the potential to re-
solve these diagnostically challenging cases.14 
Further analysis of survival data in our cohort as 
it matures will be required to improve risk 
stratification with the use of molecular markers. 
In addition, ongoing acquisition and maturation 
of detailed data on treatment and outcomes will 
aid in the delineation of markers that are predic-
tive of therapeutic response. In the meantime, 
however, the use of molecular classification can 
be integrated with other clinical, neuroimaging, 
and pathological data to devise a treatment 
strategy for individual patients.
It may transpire that distinct therapeutic 
strategies are required for effective disease con-
trol in molecular subtypes of lower-grade glioma. 
Molecular inclusion criteria and stratification in 
clinical-trial design will be necessary for a clear 
interpretation of outcomes from specific treat-
ments. The prevalence of IDH mutations in lower-
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grade glioma invites targeting of either the mu-
tant enzymes themselves or their downstream 
metabolic and epigenomic consequences, such as 
G-CIMP.52 Mutations in ATRX, CIC, and FUBP1 
have only recently been implicated in cancer 
pathogenesis, yet their specificity and preva-
lence in lower-grade glioma with an IDH muta-
tion support central roles in oncogenesis and 
argue for thorough characterization of associat-
ed signaling networks to facilitate therapeutic 
development. The genetic and clinical similari-
ties between lower-grade glioma with wild-type 
IDH and primary glioblastoma support the poten-
tial inclusion of this type of lower-grade glio-
ma within the broad spectrum of glioblastoma- 
related clinical investigation and treatment 
protocols. Finally, our integrative analysis has 
shown that all subtypes of lower-grade glioma 
rely to some extent on core signaling networks 
that have previously been implicated in glioblas-
toma pathogenesis, many of which are targeted 
by agents that are being evaluated in clinical 
trials.
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